AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Second Generation Phenylthiazole Antibiotics for Treatment of MRSA

Summary

Researchers at Purdue University have developed second generation Phenylthiazole antibiotics with enhanced pharmacokinetic properties. After synthesis, tuning, and proper treatment of the substances, one of the compounds showed significant improvement in in-vitro anti-MRSA potency. The rapid elimination of bacterial cells was achieved. This series has improved pharmacokinetic properties compared to the first generation with a better safety profile.

Technology Benefits

Improved pharmacokinetic propertiesRapid elimination of bacterial cellsSignificant improvement in in-vitro anti-MRSA potency

Technology Application

MRSA treatmentTreatment of other 'superbugs'Antibiotic development

Detailed Technology Description

Mark CushmanPurdue Medicinal Chemistry and Molecular Pharmacology

Countries

United States

Application No.

None

Country/Region

USA

For more information, please click Here